Moderna said, on Friday, that it is on its way to producing 20 million doses of its experimental coronavirus vaccine by the end of the year, while maintaining its goal of preparing 500 million to one billion doses in 2021,

according to what was reported by the British newspaper The Daily Mail. Vaccines and treatments are essential to control the Corona pandemic, which has shown no signs of slowing down and has caused more than 944,000 deaths worldwide.

Several vaccines, including those from Pfizer and AstraZeneca, are also being tested in other clinical trials in many countries of the world, including the United States and Britain. Moderna enrolled 25,296 participants out of 30,000 to complete the final phase of clinical trials. Moderna CEO Stephan Bansel said that the trial will likely provide enough data to know whether the vaccine is effective or not. “It is unlikely that the data will be available by October and that the company will know if it will work by December at the latest, in the worst-case scenario,” he added.